

Fact Sheet: KPIs and Continuous Improvement



The HTA Review recommends adoption of performance targets and mechanisms for continuous review and improvement.

The Review acknowledges the importance of KPIs in demonstrating the effectiveness of HTA reforms and overall outcomes as stated in the National Medicines Policy. It recommends adoption of jointly owned performance targets (Recommendation 15).

Proposed headline targets are:

- >90% of PBS listing within 6 months TGA registration for products demonstrating superiority and submitted to the PBAC in the first cycle following TGA submission under the parallel processing pathway.
- >90% of PBS listings within 12 months of registration for products demonstrating superiority, other than where the above applies.

Additionally, the Review recommends transparent annual reporting on instances of products claiming superiority not being listed, that timeliness of access for products with proven superiority is reviewed after 2 years, and that findings from that review inform actions to improve timeliness to access.

This recommendation is a step in the right direction. Medicines Australia will continue to advocate for inclusion of PBS listing within 60 days of registration for all submissions.

The Review also recommends arrangements to support continuous review and improvement of HTA policies and methods (Recommendation 48). This will require consultation with all stakeholders

Together with the work around access measures already underway as part of the Strategic Agreement, these recommendations will be crucial in standardising the reporting of the access gap and providing metrics that are meaningful to all stakeholders.

Reducing the delay between registration and reimbursement is a critical indicator of the effectiveness of Australia's HTA system and must be measured.

Key takeaways

- The HTA Review recommends the adoption of performance targets for products demonstrating superiority.
- Medicines Australia will continue to advocate for a target for PBS listing within 60 days of registration for all medicines.